Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis

NCT06685692 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT06685692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06685692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2024
Completion date
June 18, 2025
Enrollment
4 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol hepatitis